Abstract

  With the coronavirus disease 19 (COVID-19) causing a health crisis worldwide, researchers and clinicians are exploring different pharmacological treatments to fight against this pandemic. A leading class of drugs currently being experimented with to treat, prevent, or decrease the severity of COVID symptoms are monoclonal antibodies. Many pharmaceutical companies are constructing monoclonal antibodies by utilizing the antibodies produced by patients infected with COVID. By analyzing the antibodies' structure and using the mechanism of action of how COVID infects the host, specific and compelling monoclonal antibodies targeting the virus's pathway to infect the cells can be constructed. Regeneron and Eli Lilly and Company are two leading pharmaceutical companies currently working on monoclonal antibodies. Regeneron is currently working on a combination monoclonal antibody known as REGN-COV2. The combination therapy has shown to reduce both viral levels and improve symptoms in non-hospitalized patients. In contrast, Eli Lilly and Company's combination of bamlanivimab and etesevimab has shown to reduce viral load, symptoms, COVID-related hospitalization, and emergency room hospitalizations. This minireview aims to bring awareness of the different clinical trials involving monoclonal antibodies and their current status.

Keywords: Monoclonal Antibody; Neutralizing Antibodies; COVID-19; SARS-CoV-2; Regeneron; Bamlanivimab; Etesevimab; REGN-COV2

References

1. Hui David S., et al. “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China”. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 91 (2020): 264-266.
2. Shanmugaraj Balamurugan., et al. “Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)”. Asian Pacific Journal of Allergy and Immunology1 (2020): 10-18.
3. Kramer Axel., et al. “How long do nosocomial pathogens persist on inanimate surfaces? A systematic review”. BMC Infectious Diseases 130. (2006).
4. Harapan Harapan., et al. “Coronavirus disease 2019 (COVID-19): A literature review”. Journal of Infection and Public Health 5 (2020): 667-673.
5. Burrell C., et al. “Fenner and White's medical virology”. Academic Press; United States (2016).
6. Baxter David. “Active and passive immunity, vaccine types, excipients and licensing”. Occupational Medicine8 (2007): 552-556.
7. Bernasconi Nadia L., et al. “Maintenance of serological memory by polyclonal activation of human memory B cells. (Reports)”. Science 5601 (2002): 2199.
8. Sui Jianhua., et al. “Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants”. Journal of Virology10 (2005): 5900-5906.
9. Both Leonard., et al. “Monoclonal antibodies for prophylactic and therapeutic use against viral infections”. Vaccine 12 (2013): 1553-1559.
10. Bayry J., et al. “Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action”. Nature Reviews Rheumatology 3 (2007): 262-272.
11. Lu Roujian., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 10224 (2020): 565-574.
12. Li Wenhui., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature6965 (2003): 450-454.
13. Kuhn JH., et al. “Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus”. Cellular and Molecular Life Sciences: CMLS21 (2004): 2738-2743.
14. Hoffmann Markus., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell2 (2020): 271-280.e8.
15. Joachim Alexandre., et al. “Renin-angiotensin-aldosterone system and COVID-19 infection”. Annales d'Endocrinologie 2-3 (2020): 63-67.
16. Behl Tapan., et al. “The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions”. Life Sciences 257 (2020): 118075.
17. Hansen Johanna., et al. “Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail”. Science, American Association for the Advancement of Science (2020).
18. Baum Alina., et al. “Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies”. Science, American Association for the Advancement of Science 21 (2020).
19. “Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients”. Regeneron Pharmaceuticals Inc., investor (2020).
20. “Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 - Full Text View”. Full Text View - ClinicalTrials.gov, clinicaltrials (2020).
21. Eli Lilly and Company. “Lilly Announces Proof of Concept Data for Neutralizing Antibody LY-CoV555 in the COVID-19 Outpatient Setting”. Eli Lilly and Company (2020).
22. “Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs”. Eli Lilly and Company (2020).
23. , et al. “Study of Eli Lilly Covid-19 Drug Paused Due to Safety Concern”. The Wall Street Journal Dow Jones and Company (2020).
24. “Search of: Coronavirus - List Results”. Home – Clinical Trials (2020).

Citation

Citation: Salim Surani., et al. “COVID Monoclonal Antibodies and Current Research: Are We There Yet?". Acta Scientific Medical Sciences 4.12 (2020): 74-80.

Copyright

Copyright: © 2020 Salim Surani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.